Effect of Empagliflozin in prevention of kidney stone parameters
Phase 3
- Conditions
- urolithiasis.Calculus of kidney with calculus of ureterN20.2
- Registration Number
- IRCT20211203053261N2
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 138
Inclusion Criteria
Patients in the age range of 18 to 65 years
Patients with a history of kidney stones in the last 5 years
Exclusion Criteria
Diabetic patients
Taking antidiabetic drugs
Taking diuretic drugs
Chronic kidney disease patients
pregnancy
Patients with genital infections
Patients with urinary infections
breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 24-hour urine calcium. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary calcium to 24-hour urine volume.;24 hour Urine Oxalate. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary Oxalate to 24-hour urine volume.;24 hour urine Uric acid. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary Uric acid to 24-hour urine volume.;24 hour urine Phosphate. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary Uric acid to 24-hour urine volume.
- Secondary Outcome Measures
Name Time Method